The date when you can begin selling in a regulated market was most likely fixed many months before you had submitted any forms; that is the unpleasant lesson contained in the process of obtaining clearance for medical devices, and it applies well beyond hospitals and laboratories. Food producers, supplement companies, cosmetic firms, financial services businesses, and contractors that operate under state licensing boards all face the same situation. A decision taken early on, often in a casual manner, by individuals who are concerned with the product rather than the paperwork, decides how much evidence will later be required of you and how long you will have to wait before you can start making money. In this article, we will discuss what you should know when bringing a regulated product to market.
The reason the pattern is so clear is that the FDA provides its own clock and criteria for stopping it; in less formally regulated markets, owners have to cope with the same dynamics but with far less visibility. That’s what the device industry has already found out the hard way.
Key Takeaways on Regulated Product
|
The Review Clock Is Not The Timeline You Should Plan Around your Regulated Product
Most Class II medical devices enter the U.S. market through a premarket notification called a 510(k). The agency aims to make a decision within 90 “FDA Days”, and that expression is very significant since the days in question do not include any time during which the submission is on hold. If a reviewer requests additional information, the clock stops. According to the FDA’s 510(k) review clock rules, the sponsor has 180 calendar days in which to respond completely, may not apply for an extension beyond that period, and if the deadline is missed, the submission is treated as having been withdrawn, after which it is removed from the review system, and the company has to refile from the beginning.
That structure should alter how you interpret any published approval timeline, since the 90-day target refers to agency working time, not calendar time. A company that receives a single hold and takes four months to put together a response has, in fact, been through the review process for about seven months, even though the agency has met its target and reported no delay. If you base your launch plan, hiring plan, or fundraising runway on the published figure, you’re effectively planning based on a number that was never intended to reflect your actual experience.
People in sectors other than healthcare encounter the same issue, even though they use different types of paperwork. For example, applying for a liquor license, registering as a contractor, arranging an appointment with an insurance carrier, or having an underwriting review carried out by a payment processor, each of these has an official time limit and an actual one, and the difference between them is nearly always the number of times your application is sent back for additional information.
The Comparison You Choose Decides The Evidence You Owe for Regulated Product
A 510(k) functions on the principle of comparison. Instead of having to prove safety and effectiveness from first principles, the sponsor shows that the new device is substantially equivalent to one that is already legally available on the market, known as the predicate. The single comparison determines the whole of the submission: it decides which tests are carried out, how the intended use is phrased, and which questions the reviewers choose to ask.
That is why choosing a predicate becomes a design choice rather than an administrative one. Regulatory consultants who are involved in selecting a predicate device for 510(k) submissions discover that minor discrepancies, such as a different specimen type, a shifted cutoff value, or a change in how the results are interpreted, can greatly increase the analytical and clinical study requirements well beyond what the sponsor had budgeted, and that a true mismatch can put the 510(k) pathway at risk rather than just delaying it.
The key point is that in almost all regulated markets you are allowed to rely on precedent, and the precedent you choose determines the amount of evidence you have to produce. A food product submitted under an existing standard of identity must meet a lower burden than one making a new claim. Similarly, the same software raises different questions when it is promoted as a wellness tool than when it is marketed as a diagnostic tool. Decide on the comparison before you finalize the product, since it will show you what the product must be.
Small Manufacturers Carry The Heaviest Compliance Load
The figures involved become very uncomfortable quite quickly. According to the SBA’s Office of Advocacy, the average U.S. company spends about $13,000 per employee each year to meet federal regulatory requirements, while manufacturers pay more than double that amount, over $29,000. For small manufacturers employing fewer than 50 people, the highest regulatory compliance cost per employee is $50,100 per year, according to National Association of Manufacturers research cited in the Advocacy report’s February 2026 data summary.
If you apply it to a business with twenty employees, the figure ceases to be just a theoretical concept. It should be treated on the same footing as your two or three biggest cost areas, meriting the same level of careful examination that you would give to a lease or a payroll decision. The problem is that most of the decisions leading to that kind of spending are made early on, silently, in engineering discussions, even though no one at the time is considering any regulatory filings.
Validate The Pathway With The Same Discipline You Validate Demand
Founders in the software industry have generally learned the lesson of validating a product before committing to a full build, the key idea being to spend as little as possible to find out that no one wants what you’re developing. With regulated products, discipline has to be applied twice: you have to determine whether customers want the product and whether the version they want actually meets regulatory requirements.
Those two answers tend to contradict each other more than most people anticipate. The very feature which makes a product commercially attractive is often the same feature that causes it to be moved from a cheap regulatory route onto an expensive one. If you find out about this during a pre-submission discussion with the agency, you lose the meeting; but if you discover it after the design has been finalized and the validation studies are completed, you end up losing a whole year and a significant part of your runway.
A cheap version of the test is available to nearly anybody. So, before finalizing your specifications, write out the intended use statement or product claim precisely as you intend to submit it. Next, check the existing approvals or clearances for any that use the same wording. With public databases, you can search for these in just a day or two. If no similar cases exist, you’ll have gained valuable insight while it was still cheap to act.
Documentation for Regulated Product Earns Revenue, Not Only Approvals
All of this has a benefit which owners tend to undervalue. The same records which satisfy a regulator, including design history, validation reports, change control, and supplier qualification, are the records enterprise buyers request during vendor review. By treating compliance posture as a sales asset rather than a defensive cost, you shorten the sales process because you can address a procurement team’s questions the same week, whereas competitors remain quiet for a month trying to put together something credible.
In both the equipment and diagnostic sectors, this is clearly the case: hospital systems and reference laboratories will not initiate discussions about purchasing until they have the necessary clearance documents. In more informal markets, it appears as the unspoken reason why a deal ended up going somewhere else, and no one ever explains why.
What To Do Before You Commit The Capital
Before committing significant capital, a business consultant can help owners assess whether the regulatory pathway still supports the economics of the opportunity. Before large amounts of money are spent, three steps should be taken. You should set down your intended use or product claim in the final language early on and treat it as a design input rather than as marketing copy drafted later. To establish a precedent, look for products that have already had claims similar to yours and examine the kind of evidence those products submitted. You then need to provide for at least one round of questions, since if you assume that a request will be made and plan your schedule around the time it takes to receive a response, you’ll end up with a plan that can withstand real-world contact.
There is no need to set up a regulatory department in-house. All that is necessary is to decide that the process of obtaining approval is a business matter that should be handled on the owner’s desk with the same care and seriousness as when signing a lease or appointing a general manager. It is companies that suffer setbacks who are not usually the ones lacking the necessary expertise; rather, it is those that regarded regulatory work as something that could be handed over after the major decisions had already been made.
Frequently Asked Questions on Regulated Product
How Long Does A 510(K) Really Take?
The performance target of the FDA is to make a decision within 90 FDA Days, provided that no time is included for when the submission is placed on hold pending a request for additional information. Analysis of the total time recorded on the calendar shows that it exceeds the figure in question, since the majority of submissions receive at least one request for additional data. Therefore, you should plan according to calendar time rather than the goal.
Does Any Of This Apply Outside Healthcare?
That is the case. In every market in which a government agency or a private gatekeeper examines your product before you are permitted to sell it, the same pattern obtains. Although the details vary greatly, the pattern of an initial comparative decision establishing a higher burden of proof later on does not.
When Should A Small Company Bring In Outside Regulatory Help?
Until the design is finalized, the value of expert input decreases significantly once the specifications, claims, and validation protocols are fixed, because at that stage all remaining options become expensive. The advice given in just a few hours during the concept development phase is more valuable than a complete engagement carried out after the studies have been run.
Is A Regulated Product Worth Pursuing As A Small Business At All?
The difficulty is very real and affects smaller companies the most; it also acts as a barrier, safeguarding those who succeed in overcoming it. A product approved in a narrow field faces much less competition than an unregulated one, and this kind of protection persists in a way unlike most other competitive advantages. The price one has to pay is the cost of gaining access to a more tranquil market.
